Industry Focus

Why Alkermes once-promising depression drug failed to impress the FDA's advisory committee. Plus, how a $1.2 billion acquisition of Pacific Biosciences could move the needle at Illumina. Stocks: ALKS, ILMN, PACB

Direct download: IF_Healthcare_11072018_1.mp3
Category:general -- posted at: 3:30pm EST

1